Status:
COMPLETED
Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures
Lead Sponsor:
UCB Pharma
Conditions:
Epilepsy, Partial
Eligibility:
All Genders
1-16 years
Phase:
PHASE3
Brief Summary
To allow pediatric patients with partial onset seizures an opportunity to receive (as follow-up to studies N01009(NCT00105040)/N01103(NCT00175890) or by direct enrollment) open-label levetiracetam tre...
Eligibility Criteria
Inclusion
- Pediatric patients with partial onset seizures, with 1 to 2 anti-epileptic drugs (AEDS), with participation in previous levetiracetam pediatric studies (N01009 or N01103) or direct enrollment, for whom levetiracetam treatment will be of possible benefit
Exclusion
- Patients on a ketogenic diet
- Seizures too close together to accurately count
- Pseudoseizures
- Status epilepticus 1 month prior Visit 1
- Current diagnosis of Lennox-Gastaut Syndrome or epilepsy secondary to a progressing cerebral disease will be excluded from the study.
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
255 Patients enrolled
Trial Details
Trial ID
NCT00152516
Start Date
October 1 2004
End Date
June 1 2008
Last Update
February 12 2013
Active Locations (84)
Enter a location and click search to find clinical trials sorted by distance.
1
Mobile, Alabama, United States
2
Phoenix, Arizona, United States
3
Los Angeles, California, United States
4
Denver, Colorado, United States